European Journal of Haematology

Article	Citations
Changing patterns in the epidemiology of β‐thalassemia	138
COVID‐19 vaccine‐associated immune thrombosis and thrombocytopenia (VITT): Diagnostic and therapeutic recommendations for a new syndrome	104
COVID‐19 coagulopathy: An in‐depth analysis of the coagulation system	92
The hematologic consequences of obesity	78
Haematological manifestations of COVID‐19: From cytopenia to coagulopathy	72
Clinical course and risk factors for mortality from COVID‐19 in patients with haematological malignancies	70
Association of anticoagulation dose and survival in hospitalized COVID‐19 patients: A retrospective propensity score‐weighted analysis	63
Blinatumomab in pediatric patients with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia	39
Pairing MCL‐1 inhibition with venetoclax improves therapeutic efficiency of BH3‐mimetics in AML	37
The incidence of thrombocytopenia in adult patients receiving chemotherapy for solid tumors or hematologic malignancies	37
Real‐world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib	34
Treating secondary antibody deficiency in patients with haematological malignancy: European expert consensus	33
Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series	31
Anticoagulation strategies in extracorporeal circulatory devices in adult populations	30
The incidence, complications, and treatment of iron deficiency in pregnancy	30
Patient outcomes in light chain (AL) amyloidosis: The clock is ticking from symptoms to diagnosis	28
COVID‐19 and thalassaemia: A position statement of the Thalassaemia International Federation	26
Quality of life in patients of chronic lymphocytic leukemia using the EORTC QLQ‐C30 and QLQ‐CLL17 questionnaire	26
Current understanding and future implications of sepsis‐induced thrombocytopenia	26
CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real‐world practice	26
One‐year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab	26
Long‐term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2‐year results from two pivotal phase 3 studies	25
The role of ROTEM variables based on clot elasticity and platelet component in predicting bleeding risk in thrombocytopenic critically ill neonates	24
Fecal microbiota transfer for refractory intestinal graft‐versus‐host disease — Experience from two German tertiary centers	23
Primary pancreatic lymphoma: Clinical presentation, diagnosis, treatment, and outcome	23

Review of Vitamin B12 deficiency in pregnancy: a diagnosis not to miss as veganism and vegetarianism become more prevalent	23
The incidence and prevalence of patients with paroxysmal nocturnal haemoglobinuria and aplastic anaemia PNH syndrome: A retrospective analysis of the UK’s population‐based haematological malignancy re	23
Monitoring treatment response and disease progression in myeloma with circulating cell‐free DNA	22
SARS‐CoV‐2 infection among patients with haematological disorders: Severity and one‐month outcome in 66 Danish patients in a nationwide cohort study	22
Prognostic impact and risk factors of cancer‐associated thrombosis events in stage‐IV cancer patients treated with immune checkpoint inhibitors	22
Regional outcomes of severe acute respiratory syndrome coronavirus 2 infection in hospitalised patients with haematological malignancy	22
Long‐term follow‐up of patients with venous thromboembolism and COVID‐19: Analysis of risk factors for death and major bleeding	21
Comorbidities in multiple myeloma and implications on survival: A population‐based study	20
Diagnostic delay and characterization of the clinical prodrome in AL amyloidosis among 1523 US adults diagnosed between 2001 and 2019	20
Targeting both BET and CBP/EP300 proteins with the novel dual inhibitors NEO2734 and NEO1132 leads to anti‐tumor activity in multiple myeloma	20
Comorbidities and complications in adults with pyruvate kinase deficiency	19
Effectiveness and safety of apixaban and rivaroxaban for acute venous thromboembolism therapy in patients with extremes in bodyweight	19
Iron chelation therapy	19
Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)	19
Clinical prevalence and outcome of cardiovascular events in the first 100 days postallogeneic hematopoietic stem cell transplant	19
Favorable COVID‐19 course despite significant comorbidities in a ruxolitinib‐treated patient with primary myelofibrosis	18
Reasons and consequences of COVID‐19 vaccine failure in patients with chronic lymphocytic leukemia	18
Combination of myeloproliferative neoplasm driver gene activation with mutations of splice factor or epigenetic modifier genes increases risk of rapid blastic progression	18
Characteristics of peripheral blood differential counts in hospitalized patients with COVID‐19	18
Sickle cell trait and the potential risk of severe coronavirus disease 2019—A mini‐review	17
Clinical predictors of SARS‐CoV‐2 neutralizing antibody titers in COVID‐19 convalescents: Implications for convalescent plasma donor recruitment	16
Emicizumab treatment: Impact on coagulation tests and biological monitoring of haemostasis according to clinical situations (BIMHO group proposals)	16
The prognostic impact of variant allele frequency (VAF) in TP53 mutant patients with MDS: A systematic review and meta‐analysis	16
Outcome of COVID‐19 in multiple myeloma patients in relation to treatment	16
Validation of the HScore and the HLH‐2004 diagnostic criteria for the diagnosis of hemophagocytic lymphohistiocytosis in a multicenter cohort	15
T cell–mediated autoimmunity in immune thrombocytopenia	15
Daratumumab for relapsed AL amyloidosis—When cumulative real‐world data precedes clinical trials: A multisite study and systematic literature review	15
Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvement	15
Bone lesions in hairy cell leukemia: Diagnosis and treatment	14
Organ sparing total marrow irradiation compared to total body irradiation prior to allogeneic stem cell transplantation	14
The role of oral iron in the treatment of adults with iron deficiency	14
Impact of a comprehensive geriatric assessment on decision‐making in older patients with hematological malignancies	14
Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma in the real world	13
Impact of body mass index on relapse in children with acute lymphoblastic leukemia treated according to Nordic treatment protocols	13
Janus‐faced course of COVID‐19 infection in patients with hematological malignancies	13
Acquired aplastic anemia following SARS‐CoV‐2 vaccination	13
Early report on the severity of COVID‐19 in hematologic patients infected with the SARS‐CoV2 omicron variant	13
The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors in France, Germany and the United Kingdom: Patient‐reported insights on symptoms and qual	12
Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group	12
Assessing the risk of thromboembolism in cancer patients receiving immunotherapy	12
A 3′ tRNA‐derived fragment produced by tRNALeuAAG and tRNALeuTAG is associated with poor prognosis in B‐cell chronic lymphocytic leukemia, independently of classical prognostic f	12
Role of pre‐transplant MRD level detected by flow cytometry in recipients of allogeneic stem cell transplantation with AML	12
Treatment patterns and clinical outcomes of tyrosine kinase inhibitors in chronic‐phase CML in clinical practice: 3‐year European SIMPLICITY data	12
The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: A multicentre collaborative study	12
Letter to the Editor: Fine‐needle aspiration cytology and core‐needle biopsy in the diagnosis of lymphadenopathies: Words of endorsement	12
Safety of apixaban compared to warfarin in hemodialysis patients: Do antiplatelets make a difference?	12
Real‐world data on voxelotor to treat patients with sickle cell disease	12
White blood count, D‐dimers, and ferritin levels as predictive factors of pulmonary embolism suspected upon admission in noncritically ill COVID‐19 patients: The French multicenter CLOTVID retrospecti	12
Combination of brentuximab‐vedotin and ifosfamide, carboplatin, etoposide in relapsed/refractory peripheral T‐cell lymphoma	11
Lymph node core needle biopsy for the diagnosis of lymphoproliferative disorders: A word of caution	11

Treatment horizon in multiple myeloma	11
Next‐generation sequencing in hypoplastic bone marrow failure: What difference does it make?	11
Recombinant factor VIII Fc for the treatment of haemophilia A	11
Prognostic impact of pretransplant measurable residual disease assessed by peripheral blood WT1‐mRNA expression in patients with AML and MDS	11
Cellular and humoral response to the fourth BNT162b2 mRNA COVID‐19 vaccine dose in patients with CLL	11
Lymph node core biopsies reliably permit diagnosis of lymphoproliferative diseases. Real‐World Experience from 554 sequential core biopsies from a single centre	10
Principles of care for acquired hemophilia	10
Clinical efficacy of mogamulizumab for relapsed/refractory aggressive adult T‐cell leukemia/lymphoma: A retrospective analysis	10
Immune thrombocytopenic purpura secondary to COVID‐19 vaccination: A systematic review	10
Refractory autoimmune cytopenias in pediatric Evans syndrome with underlying systemic immune dysregulation	10
Long‐term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome–positive leukemia resistant or intolerant to prior therapy	10
VEXAS syndrome: A review of bone marrow aspirate and biopsies reporting myeloid and erythroid precursor vacuolation	10
Characteristics and recognition of early infections in patients treated with commercial anti‐CD19 CAR‐T cells	10
Molecular pharmacology in complement‐mediated hemolytic disorders	10
Haploidentical transplantation in pediatric non‐malignant diseases: A retrospective analysis on behalf of the Spanish Group for Hematopoietic Transplantation (GETH)	10
Application of comprehensive geriatric assessment in predicting early mortality among elder patients with B‐cell lymphoma receiving immunochemotherapy	10
Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high‐risk cytogenetics: IKEMA subgroup analysis	10
Outcome data from >10 000 multiple myeloma patients in the Danish and Swedish national registries	10
The hemostatic and thrombotic complications of liver disease	9
Clonal cytopenia of undetermined significance (CCUS) with dysplasia is enriched for MDS‐type molecular findings compared to CCUS without dysplasia	9
MALT‐1 as a novel therapeutic target for adult T‐cell leukemia	9
Anti‐thymocyte globulin and post‐transplant cyclophosphamide predisposes to inferior outcome when using cryopreserved stem cell grafts	9
Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia	9
Management of rare inherited bleeding disorders: Proposals of the French Reference Centre on Haemophilia and Rare Coagulation Disorders	9
CAR‐T cell therapy for patients with hematological malignancies. A systematic review	9
Doubtful precipitation of hemolysis by hydroxychloroquine in glucose‐6‐phosphate dehydrogenase‐deficient patient with COVID‐19 infection	9
Association between red blood cell transfusion dependence and burden in patients with myelodysplastic syndromes: A systematic literature review and meta‐analysis	9
Lymphoid malignancy in common variable immunodeficiency in a single‐center cohort	9
Late occurrence of progressive multifocal leukoencephalopathy after anti‐CD19 chimeric antigen receptor T‐cell therapy	9
High levels of immunoglobulin expression predict shorter overall survival in patients with acute myeloid leukemia	9
Pain and functional disability amongst adults with moderate and severe haemophilia from the Irish personalised approach to the treatment of haemophilia (iPATH) study	9
Image‐guided core needle biopsy as the first‐line diagnostic approach in lymphoproliferative disorders—A review of the current literature	9
Progressive multifocal leukoencephalopathy in the context of newer therapies in hematology and review of new treatment strategies	9
Matched sibling donor stem cell transplantation for sickle cell disease: Results from the Spanish group for bone marrow transplantation in children	8
Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma	8
Autoimmune disease is associated with a lower risk of progression in monoclonal gammopathy of undetermined significance	8
Adverse prognostic impact of regulatory T‐cells in testicular diffuse large B‐cell lymphoma	8
Impact of platelets on major thrombosis in patients with a normal white blood cell count in essential thrombocythemia	8
CAR‐T cell therapy in hematological malignancies: Where are we now and where are we heading for?	8
POEMS syndrome: A multisystem clonal disorder	8
Thromboembolic complications in autoimmune hemolytic anemia: Retrospective study	8
Survival trends in elderly myeloma patients	8
COVID‐19 complicated by parainfluenza co‐infection in a patient with chronic lymphocytic leukemia	7
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents	7
Use of midostaurin in mixed phenotype acute leukemia with FLT3 mutation: A case series	7
mRNA COVID‐19 vaccines in patients with chronic lymphocytic leukemia: A systematic review and meta‐analysis	7
Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple‐class relapsed/refractory multiple myeloma (RRMM)	7
Bleeding complications in bcr‐abl‐negative myeloproliferative neoplasms (MPN): A retrospective single‐center study of 829 MPN patients	7
Intracranial hemorrhage in newly diagnosed non‐promyelocytic acute myeloid leukemia patients admitted for intensive induction chemotherapy	7
Data‐driven analysis of the kinetics of the JAK2V617F allele burden and blood cell counts during hydroxyurea treatment of patients with polycythemia vera, essential thrombocythemia, and primary	7
Neutralizing antibody responses against SARS‐CoV‐2 in patients with plasma cell disorders who are on active treatment after two doses of mRNA vaccination	7
Survival in autoimmune hemolytic anemia remains poor, results from a nationwide cohort with 37 years of follow‐up	7
JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: Final results of a phase II, open label, multicentre clinical trial (JeRiCHO)	7
The role of CUDC‐907, a dual phosphoinositide‐3 kinase and histone deacetylase inhibitor, in inhibiting proliferation of adult T‐cell leukemia	7
Outcomes of relapsed or refractory acute myeloid leukemia patients failing venetoclax‐based salvage therapies	7
Racial and ethnic differences in sickle cell disease within the United States: From demographics to outcomes	7
Higher average chemotherapy dose intensity improves prognosis in patients with aggressive adult T‐cell leukemia/lymphoma	7
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics	7
Pre‐transplant minimal residual disease assessment and transplant‐related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantation	7
Clonal haematopoiesis of indeterminate potential and impaired kidney function—A Danish general population study with 11 years follow‐up	7
Despite warnings, co‐medication with proton pump inhibitors and dasatinib is common in chronic myeloid leukemia, but XS004, a novel oral dasatinib formulation, provides reduced pH‐depe	7
Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?	7
Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: A pharmaco‐economic assessment	7
A nationwide study on inpatient opportunistic infections in patients with chronic lymphocytic leukemia in the pre‐ibrutinib era	6
Translation, validation, and usability of the International Society on Thrombosis and Haemostasis Bleeding Assessment Tool (Self‐ISTH‐BAT)	6
Long‐term tolerability of phosphodiesterase‐5 inhibitors in pulmonary hypertension of sickle cell disease	6
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients	6
Soluble programmed cell death protein 1 (sPD‐1) and the soluble programmed cell death ligands 1 and 2 (sPD‐L1 and sPD‐L2) in lymphoid malignancies	6
Platelet transfusion and tranexamic acid to prevent bleeding in outpatients with a hematological disease: A Dutch nationwide survey	6
Comparison of ibrutinib and idelalisib plus rituximab in real‐life relapsed/resistant chronic lymphocytic leukemia cases	6
Efficacy of Helicobater pylori eradication in patients with diffuse large B‐cell lymphoma of the stomach: A systematic review	6
Characteristics and potential biomarkers of adult sickle cell patients with chronic pain	6
Clinical utility of targeted next‐generation sequencing panel in routine diagnosis of hereditary hemolytic anemia: A national reference laboratory experience	6
Integrin expression and adhesivity to fibronectin in primary acute myeloid leukemia cells: Impact of NPM1 and FLT3 mutations	6
Direct oral anticoagulants versus warfarin in patients with single antibody‐positive anti‐phospholipid syndrome	6
Oxidative stress, inflammation, blood rheology, and microcirculation in adults with sickle cell disease: Effects of hydroxyurea treatment and impact of sickle cell syndrome	6
“Ex‐vivo” T‐cell depletion in allogeneic hematopoietic stem cell transplantation: New clinical approaches for old challenges	6
Retrospective analysis of the safety of peripherally inserted catheters versus implanted port catheters during first‐line treatment for patients with diffuse large B‐cell lymphoma	6
Post‐transplant maintenance therapy in patients with FLT3‐mutated acute myeloid leukemia: Real‐world treatment patterns and outcomes	6
The management, outcome, and postpartum disease course of 41 pregnancies in 20 women with polycythemia vera	6

A retrospective study of treosulfan versus busulfan‐based conditioning in pediatric patients	6
Systematic review of hematuria and acute renal failure with tranexamic acid	6
Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis	6
Beneficial effects of eculizumab regardless of prior transfusions or bone marrow disease: Results of the International Paroxysmal Nocturnal Hemoglobinuria Registry	6
Prevalence and risk factors for Pulmonary Hypertension associated with chronic Myeloproliferative Neoplasms	6
Life expectancy and cause of death in individuals with haemophilia A and B in Norway, 1986‐2018	6
Assessment of von Willebrand disease and pregnancy outcomes at regional Australian hospitals	5
Major central nervous system complications after allogeneic stem cell transplantation: A large retrospective study on 888 consecutive adult patients	5
Risk factors for invasive fungal infection in 5‐azacytidine treated patients with acute myeloid leukemia and myelodysplastic syndrome	5
Bone marrow CD3+CD56+ regulatory T lymphocytes (TR3−56 cells) are inversely associated with activation and expansion of bon	5
Long‐term outcome in patients with follicular lymphoma following high‐dose therapy and autologous stem cell transplantation	5
Teclistamab‐cqyv in multiple myeloma	5
Clinical outcomes following bone marrow transplantation in patients with sickle cell disease: A cohort study of US Medicaid enrollees	5
Outcomes after intensive care unit admission in newly diagnosed diffuse large B‐cell lymphoma patients: A real‐life study	5
Perioperative management for patients with von Willebrand disease: Defining the optimal approach	5
Validation of the Alternative International Prognostic Score‐E (AIPS‐E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O‐CLL1‐GISL protocol	5
Evaluation of soluble fibrin monomer complex in patients in SARS‐CoV‐2 COVID‐19 infection‐associated coagulopathy	5
Predicting primary treatment failure using interim FDG‐PET scanning in diffuse large B‐cell lymphoma	5
Transfusion requirements in patients with COVID‐19	5
Implementation of International Prognostic Index with flow cytometry immunophenotyping for better risk stratification of chronic lymphocytic leukemia	5
The evolution of immune dysfunction in multiple myeloma	5
Clinical and microbiological impact of long‐term discontinuation of fluoroquinolone prophylaxis in haematological patients with prolonged profound neutropenia	5
Baseline serum B‐cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma	5
Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma: A retro‐prospective observational study	5
Venetoclax‐based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemia	5
Desmopressin as a hemostatic and blood sparing agent in bleeding disorders	5
A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma	5
Novel somatic alterations in unicentric and idiopathic multicentric Castleman disease	5
Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first‐line systemic treatment or best supportive care: A multicenter inte	5
Incidence and socioeconomic factors in older adults with acute myeloid leukaemia: Real‐world outcomes from a population‐based cohort	5
Circulating endothelial cells and endothelial progenitor cells as potential predictors of acute GVHD after allogeneic hematopoietic stem cell transplantation	5
Post‐transplantation erythrocytosis in kidney transplant recipients—A retrospective cohort study	5
Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of the non‐interventional study POSEIDON and comparison with the pivotal phase 3 clinical trial	5
Prevalence of non‐adherence and non‐compliance during maintenance therapy in adults with acute lymphoblastic leukemia and their associations with survival	5
Non‐myeloablative matched sibling stem cell transplantation with the optional reinforced stem cell infusion for patients with hemoglobinopathies	5
Incidence of adult primary immune thrombocytopenia in England—An update	5
Chimeric antigen receptor T cells for acute myeloid leukemia	4
Standardization for obtaining blood viscosity: A systematic review	4
15‐color highly sensitive flow cytometry assay for post anti‐CD19 targeted therapy (anti‐CD19‐CAR‐T and blinatumomab) measurable residual disease assessment in B‐lymphoblastic le	4
Long‐term outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab in a real‐world setting	4
Azacitidine for relapse of acute myeloid leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation, multicenter PALG analysis	4
Non‐driver gene mutation analysis in a large cohort of polycythemia vera and essential thrombocythemia	4
Patterns of previous and secondary malignancies in patients with multiple myeloma	4
Survival, causes of death, and the prognostic role of comorbidities in chronic lymphocytic leukemia in the pre‐ibrutinib era: A population‐based study	4
Extended treatment response to imatinib in Rosai‐Dorfman disease	4
Luspatercept, a two‐edged sword in beta‐thalassemia‐associated paravertebral extramedullary hematopoietic masses (EHMs)	4
Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate‐risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute	4
Systematic review of survival outcomes for relapsed or refractory adult T‐cell leukemia‐lymphoma	4
A low‐dose rituximab regimen for first‐line treatment of acquired haemophilia A	4
Histology of the spleen in immune thrombocytopenia: clinical‐pathological characterization and prognostic implications	4
Income, education and their impact on treatments and survival in patients with myelodysplastic syndromes	4
Comorbidity profile of adult survivors at 20 years following allogeneic hematopoietic cell transplantation	4
Efficacy of COVID‐19 vaccination in adult patients with sickle cell disease during the Omicron wave in France	4
Tyrosine kinase inhibitors and tumor lysis syndrome in hematologic malignancies: A systemic review	4
Efficacy and safety of regimens used for the treatment of multicentric Castleman disease: A systematic review	4
Anti‐thymocyte Globulin and Post‐Transplant Cyclophosphamide do not abrogate the inferior outcome risk conferred by human leukocyte antigen‐A and ‐B mismatched donors	4
A regulatory element in the 3′‐untranslated region of CEBPA is associated with myeloid/NK/T‐cell leukemia	4
Myocardial strain is associated with adverse cardiac events in patients treated with chimeric antigen receptor (CAR) T‐cell therapy	4
Hematopoietic cell transplantation for Diamond Blackfan anemia: A report from the Pediatric Group of the Brazilian Bone Marrow Transplantation Society	4
Failure of mobilization of hematopoietic stem cells associated with elevated serum levels of anti‐CD38 monoclonal antibody	4
Retrospective study of treatment patterns and outcomes post‐lenalidomide for multiple myeloma in Canada	4
Herombopag promotes platelet engraftment and decreases platelet transfusion after allogeneic hematopoietic stem cell transplantation	4
The impact of COVID‐19 in the management of AL amyloidosis and Immunoglobulin Deposition Disease: A single‐center experience	4
Antibody titers after SARS‐CoV‐2 mRNA vaccination in patients with aplastic anemia—A single‐center study	4
Febrile neutropenia in patients with acute myeloid leukemia: Outcome in relation to qSOFA score, C‐reactive protein, and blood culture findings	4
Graft‐versus‐mastocytosis effect after donor lymphocyte infusion: Proof of principle	4
Radiation‐free myeloablative conditioning consisting of fludarabine added to full‐dose busulfan and cyclophosphamide in single‐unit cord blood transplantation for adults	4
Screening for occult cancer after unprovoked venous thromboembolism: Assessing the current literature and future directions	4
Congenital erythrocytosis	4
Characterization and prognostic implication of delayed complete response in AL amyloidosis	4
Immune‐related adverse events in cancer patients being treated with immune checkpoint inhibitors	4
VEGFR2 and VEGFA polymorphisms are not associated with an inferior prognosis in Caucasian patients with aggressive B‐cell lymphoma	4
Clearance of bone marrow mast cells after hypomethylating agent and venetoclax for systemic mastocytosis associated with myeloid neoplasia	4
Long‐term tolerability and efficacy after initial PegIFN‐α addition to dasatinib in CML‐CP: Five‐year follow‐up of the NordCML007 study	4
Crovalimab treatment in patients with paroxysmal nocturnal haemoglobinuria: Long‐term results from the phase I/II COMPOSER trial	4
Clinical implications of NUP98::NSD1 fusion at diagnosis in adult FLT3‐ITD positive AML	4
Clinical efficacy of retreatment of daratumumab‐based therapy (D2) in daratumumab‐refractory multiple myeloma	4
Antigen loss following CAR‐T cell therapy: Mechanisms, implications, and potential solutions	4
Artificial intelligence in the prediction of venous thromboembolism: A systematic review and pooled analysis	4
Full or intensity‐reduced high‐dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma	4
Pixantrone in patients with relapsed/refractory diffuse large B‐cell lymphoma: A real‐life, retrospective, multicenter trial on behalf of the “RTL” (Regional Tuscan Lymphoma network)	4
Single UM171‐expanded cord blood transplant can cure severe idiopathic aplastic anemia in absence of suitable donors	4
Autologous stem cell transplantation vs bortezomib based chemotheraphy for the first‐line treatment of systemic light chain amyloidosis in the UK	4
Sutimlimab provides clinically meaningful improvements in patient‐reported outcomes in patients with cold agglutinin disease: Results from the randomised, placebo‐controlled, Phase 3 CADENZA	4
Vitamin E and acute graft‐versus‐host disease after myeloablative allogeneic hematopoietic cell transplantation	4
Response rates of extra‐nodal diffuse large B cell lymphoma to anti‐CD19‐CAR T cells: A real word retrospective multicenter study	4
Highly expressed genes in multiple myeloma cells – what can they tell us about the disease?	4
Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: Results of a comparative performance analysis	4
Treatment patterns and disease course of previously untreated Primary Central Nervous System Lymphoma: Feasibility of MTX‐based regimens in clinical routine	4
Selective ABO immunoadsorption in hematopoietic stem cell transplantation with major ABO incompatibility	4
Changes in body mass index during treatment of childhood acute lymphoblastic leukemia with the Nordic ALL2008 protocol	4
Effect of eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuria with or without high disease activity: Real‐world findings from the International Paroxysmal Nocturnal He	3
Incidence, prognostic factors, and survival outcomes in patients with blastic plasmacytoid dendritic cell neoplasm: A retrospective study in the Surveillance, Epidemiology, and End Results database	3
Haematology Outcomes Network in Europe (HONEUR)—A collaborative, interdisciplinary platform to harness the potential of real‐world data in hematology	3
Maintenance therapy in transplant ineligible adults with newly‐diagnosed multiple myeloma: A systematic review and meta‐analysis	3